BioSpace News Archive

Biotech Beach

Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 30, 2023

Sientra, Inc. announced that on June 27, 2023, the Company approved equity award grants under the Sientra Inc. Inducement Plan to 20 new employees.

June 30, 2023
·
4 min read
Genetown

Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO ® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis.

June 30, 2023
·
9 min read
Biotech Beach

Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

Capricor Therapeutics (NASDAQ: CAPR) today announced positive 24-month safety and efficacy results from its ongoing HOPE-2 open label extension (OLE) study with its lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD).

June 30, 2023
·
8 min read
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for VYVGART® (efgartigimod alfa injection), a first-in-class neonatal Fc receptor (FcRn) antagonist, as an add on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

June 30, 2023
·
8 min read
Drug Development

ESMO GI Data: Agenus’ Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer

Immuno-oncology leader, Agenus (Nasdaq: AGEN), shared promising data today from its Phase 1b trial on the botensilimab and balstilimab combination at a late-breaking session at the 2023 ESMO World Congress on Gastrointestinal Cancer (ESMO GI).

June 30, 2023
·
7 min read
Drug Development

New 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial and Sustained Improvement of Motor Function in Phase 2 TOPAZ Trial Patients with Nonambulatory Spinal Muscular Atrophy

Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced new data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes at 36 months of treatment with apitegromab.

June 30, 2023
·
13 min read
Resverlogix Announces Warrant Repricing and One-Year Extension

Resverlogix Corp. (TSX: RVX) (“Resverlogix” or the “Company”) announces that certain of its 27,461,157 common share purchase warrants

June 30, 2023
·
3 min read
Drug Development

New Preliminary Findings on Potential Response Indicator of Rakuten Medical’s Alluminox Treatment from Phase 2 Window of Opportunity Study at SNMMI 2023

Rakuten Medical, Inc. announced that new interim evaluation data from the ASP-1929-103 study has been presented at the Society of Nuclear Medicine and Molecular Imaging 2023 Annual Meeting held from June 24 to 27.

June 30, 2023
·
8 min read
Drug Development

Toragen, Inc. Announces Initiation of Phase 1 Trial of TGN-S11 in Patients with Human Papillomavirus-Induced Cancer

Toragen, Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced that it has initiated a Phase 1 clinical trial to evaluate its first drug candidate.

June 30, 2023
·
1 min read
Business

Stryker to announce financial results for its second quarter of fiscal year 2023

Stryker announced that it will report financial results for second quarter of fiscal year 2023 on Thursday, August 3, 2023.

June 30, 2023
·
1 min read